LA BioMed Researchers Find Novel NDV-3 Vaccine Protects Against MRSA

In the U.S. and around the globe, skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA) continue to endanger the health and lives of patients and otherwise healthy individuals. Treatment is difficult because MRSA is resistant to many antibiotics, and the infections can recur, placing family members and other close contacts at risk of infection.
 
A study reported today in the Proceedings of the National Academy of Sciences USA holds new hope for preventing or reducing the severity of infections caused by MRSA. In the study, infectious disease specialists at the Los Angeles Biomedical Research Institute (LA BioMed) reported that a new investigational vaccine, NDV-3, employing the recombinant protein Als3, can mobilize the immune system to fight off MRSA skin infections in an experimental model. The researchers found the vaccine works by enhancing molecular and cellular immune defenses of the skin in response to MRSA and other S. aureus bacteria in disease models.
 
"This is the first published study to demonstrate the effectiveness of a cross-kingdom recombinant vaccine against MRSA skin infections," says Dr. Michael R. Yeaman, lead author of the study. "NDV-3 is unique as it is the first vaccine to demonstrate it can be effective in protecting against infections caused by both S. aureus and the fungus Candida albicans. NDV-3 represents a novel approach to vaccine design."
 
The research team found the NDV-3 vaccine reduced severity and progression of skin infection in a model of the MRSA-caused disease, and prevented MRSA invasion from the skin to deeper tissues. The team said these findings support further evaluation of NDV-3 to address disease caused by S. aureus in humans. NDV-3 has been licensed to NovaDigm Therapeutics, Inc. and has already been found to be well-tolerated and capable of producing immune responses in human clinical trials similar to those observed to be effective in the present disease model.
 
A vaccine to prevent or minimize infections caused by S. aureus could significantly improve public health because this pathogen is the leading cause of skin and skin structure infections, which can lead to life-threatening blood infections. It is also a significant cause of surgical or traumatic wound infections, diabetic skin lesions, bloodstream infections and pneumonia or endocarditis.
 
"Up to one-third of patients diagnosed with invasive S. aureus infections die, accounting for more annual deaths than HIV, tuberculosis and viral hepatitis combined," Yeaman says. "A vaccine that could prevent or lessen the severity of MRSA infections would be a significant advance in patient care and public health."
 
The study was funded, in part, by National Institutes of Health grants AI-111661 and AI-063382; U.S. Department of Defense grant W81XWH-10-2-0035, and NovaDigm Therapeutics, Inc.
 
Source: LA BioMed